Genprex Secures Patent for Reqorsa Gene Therapy in Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Source: PRnewswire
- Patent Approval: Genprex has received a Notice of Allowance from the Canadian Intellectual Property Office for its Reqorsa gene therapy patent, covering its use in combination with PD-1 or PD-L1 antibodies, which strengthens the company's intellectual property portfolio and enhances its competitive position in the Acclaim-3 clinical trial.
- Clinical Trial Progress: The Acclaim-3 trial is evaluating the combination of Reqorsa and Genentech's Tecentriq® in patients with extensive stage small cell lung cancer, with plans to enroll approximately 50 patients, aiming to determine the 18-week progression-free survival rate, providing critical data for future treatment strategies.
- Market Demand Insight: According to the Canadian Cancer Society, an estimated 32,900 people will be diagnosed with lung cancer in Canada in 2026, making it the leading cause of cancer death, which presents a significant market opportunity for Genprex's therapeutic solutions.
- Strategic Implications: Securing this patent not only solidifies Genprex's intellectual property foundation in cancer treatment but also lays the groundwork for future innovative treatment strategies, further driving the company's expansion in the global market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GNPX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GNPX
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Genprex Secures Patent for Reqorsa Gene Therapy in Cancer Treatment
- Patent Approval: Genprex has received a Notice of Allowance from the Canadian Intellectual Property Office for its Reqorsa gene therapy patent, covering its use in combination with PD-1 or PD-L1 antibodies, which strengthens the company's intellectual property portfolio and enhances its competitive position in the Acclaim-3 clinical trial.
- Clinical Trial Progress: The Acclaim-3 trial is evaluating the combination of Reqorsa and Genentech's Tecentriq® in patients with extensive stage small cell lung cancer, with plans to enroll approximately 50 patients, aiming to determine the 18-week progression-free survival rate, providing critical data for future treatment strategies.
- Market Demand Insight: According to the Canadian Cancer Society, an estimated 32,900 people will be diagnosed with lung cancer in Canada in 2026, making it the leading cause of cancer death, which presents a significant market opportunity for Genprex's therapeutic solutions.
- Strategic Implications: Securing this patent not only solidifies Genprex's intellectual property foundation in cancer treatment but also lays the groundwork for future innovative treatment strategies, further driving the company's expansion in the global market.
See More
Genprex to Participate in BIO International Convention
- Convention Participation: Genprex will attend the BIO International Convention from June 22-25, 2026, in San Diego, California, which is expected to gather over 20,000 biotech industry leaders, showcasing its advancements in gene therapies for cancer and diabetes.
- Executive Attendance: Senior Vice President Thomas Gallagher will be present to conduct one-on-one meetings with industry groups, providing detailed insights into Genprex's gene therapies, aiming to strengthen connections with potential partners.
- Clinical Trial Progress: Genprex's lead product candidate, Reqorsa® Gene Therapy, is currently undergoing two clinical trials for non-small cell lung cancer and small cell lung cancer, both of which have received Fast Track Designation from the FDA, indicating significant market potential in cancer treatment.
- Diabetes Treatment Innovation: The company's GPX-002 gene therapy aims to deliver Pdx1 and MafA genes directly to the pancreas through a novel infusion process, potentially offering new treatment options for Type 1 and Type 2 diabetes patients, thereby expanding its product pipeline.
See More
GENPREX AWARDED PATENT BY ISRAEL PATENT OFFICE FOR COMBINING REQORSA® GENE THERAPY WITH PD-1 ANTIBODIES IN CANCER TREATMENT
Patent Grant: GENPREX has received a patent grant from the Israel Patent Office for its combination therapy involving REQORSA® gene therapy and PD-1 antibodies.
Cancer Treatment: The patented combination is aimed at treating cancer, highlighting GENPREX's innovative approach in oncology.
See More
Genprex Partners with UT MD Anderson to Research Lung Cancer Biomarkers
- Research Agreement Signed: Genprex has entered into a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that may predict patient response to Reqorsa gene therapy, demonstrating the company's commitment to personalized cancer treatment.
- Biomarker Discovery: Researchers have identified TROP2 and PTEN as potential biomarkers in preclinical studies, which may increase the likelihood of patient response to Reqorsa, thereby optimizing patient selection strategies for clinical trials.
- Clinical Trial Progress: The Acclaim-1 and Acclaim-3 clinical trials are currently underway, with the former combining Reqorsa with AstraZeneca's Tagrisso and the latter with Genentech's Tecentriq, both showing good tolerability and early signs of efficacy.
- Long-term Treatment Effects: In the Acclaim-1 trial, one patient experienced over 42 months of progression-free survival following Reqorsa treatment, indicating that this therapeutic approach may offer significant long-term benefits for certain patients.
See More
Genprex Unveils Positive Data on Reqorsa Gene Therapy for Lung Cancer
- Preclinical Data Presentation: Genprex will present positive preclinical data on its lead drug candidate, Reqorsa, at the 2026 AACR Annual Meeting, indicating its multifaceted potential in treating non-small cell lung cancer, which could provide new therapeutic options for patients.
- Biomarker Discovery: Researchers identified TROP2 and PTEN as potential biomarkers for response to TUSC2 gene therapy, a finding that could refine patient selection strategies and enhance the therapeutic efficacy of Reqorsa, holding significant clinical application value.
- Enhanced Antitumor Activity: In mouse models, the combination of Quar Oze with other drugs resulted in a 79% tumor shrinkage, demonstrating its potential as an adjunct therapy, particularly for patients with resistance, which is crucial for advancing treatment options.
- Immune Enhancement Effects: The restoration of TUSC2 significantly boosted natural killer cell cytotoxicity, indicating that Reqorsa not only targets tumor cells directly but also activates the immune system, supporting its development as a dual-function therapeutic approach.
See More
Genprex to Participate in BIO Europe Spring Conference
- Executive Attendance: Genprex's CEO Ryan Confer and Senior VP of Intellectual Property Thomas Gallagher will attend the BIO Europe Spring conference in Lisbon from March 23-25, 2026, showcasing the company's advancements in gene therapies for cancer and diabetes to attract potential investors and partners.
- One-on-One Meeting Opportunities: Throughout the conference, Genprex executives will conduct one-on-one meetings with industry groups to provide an overview of the company's gene therapies, with over 3,700 executives from biotech, pharma, and finance expected to participate, fostering business development and collaboration opportunities.
- Clinical Trial Progress: Genprex's lead product candidate, Reqorsa® gene therapy, is currently undergoing two clinical trials for NSCLC and SCLC, both of which have received FDA Fast Track Designation, indicating the company's potential and competitiveness in the cancer treatment market.
- Diabetes Treatment Innovation: Genprex's diabetes gene therapy GPX-002 delivers Pdx1 and MafA genes directly to the pancreas through a novel infusion process, aiming to transform pancreatic alpha cells into functional beta-like cells, potentially offering new treatment options for diabetes patients and enhancing the company's position in the diabetes treatment market.
See More
Genprex Secures Patent for Reqorsa Gene Therapy in Cancer Treatment
- Patent Approval: Genprex has received a Notice of Allowance from the Canadian Intellectual Property Office for its Reqorsa gene therapy patent, covering its use in combination with PD-1 or PD-L1 antibodies, which strengthens the company's intellectual property portfolio and enhances its competitive position in the Acclaim-3 clinical trial.
- Clinical Trial Progress: The Acclaim-3 trial is evaluating the combination of Reqorsa and Genentech's Tecentriq® in patients with extensive stage small cell lung cancer, with plans to enroll approximately 50 patients, aiming to determine the 18-week progression-free survival rate, providing critical data for future treatment strategies.
- Market Demand Insight: According to the Canadian Cancer Society, an estimated 32,900 people will be diagnosed with lung cancer in Canada in 2026, making it the leading cause of cancer death, which presents a significant market opportunity for Genprex's therapeutic solutions.
- Strategic Implications: Securing this patent not only solidifies Genprex's intellectual property foundation in cancer treatment but also lays the groundwork for future innovative treatment strategies, further driving the company's expansion in the global market.
See More
Genprex to Participate in BIO International Convention
- Convention Participation: Genprex will attend the BIO International Convention from June 22-25, 2026, in San Diego, California, which is expected to gather over 20,000 biotech industry leaders, showcasing its advancements in gene therapies for cancer and diabetes.
- Executive Attendance: Senior Vice President Thomas Gallagher will be present to conduct one-on-one meetings with industry groups, providing detailed insights into Genprex's gene therapies, aiming to strengthen connections with potential partners.
- Clinical Trial Progress: Genprex's lead product candidate, Reqorsa® Gene Therapy, is currently undergoing two clinical trials for non-small cell lung cancer and small cell lung cancer, both of which have received Fast Track Designation from the FDA, indicating significant market potential in cancer treatment.
- Diabetes Treatment Innovation: The company's GPX-002 gene therapy aims to deliver Pdx1 and MafA genes directly to the pancreas through a novel infusion process, potentially offering new treatment options for Type 1 and Type 2 diabetes patients, thereby expanding its product pipeline.
See More
GENPREX AWARDED PATENT BY ISRAEL PATENT OFFICE FOR COMBINING REQORSA® GENE THERAPY WITH PD-1 ANTIBODIES IN CANCER TREATMENT
Patent Grant: GENPREX has received a patent grant from the Israel Patent Office for its combination therapy involving REQORSA® gene therapy and PD-1 antibodies.
Cancer Treatment: The patented combination is aimed at treating cancer, highlighting GENPREX's innovative approach in oncology.
See More
Genprex Partners with UT MD Anderson to Research Lung Cancer Biomarkers
- Research Agreement Signed: Genprex has entered into a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that may predict patient response to Reqorsa gene therapy, demonstrating the company's commitment to personalized cancer treatment.
- Biomarker Discovery: Researchers have identified TROP2 and PTEN as potential biomarkers in preclinical studies, which may increase the likelihood of patient response to Reqorsa, thereby optimizing patient selection strategies for clinical trials.
- Clinical Trial Progress: The Acclaim-1 and Acclaim-3 clinical trials are currently underway, with the former combining Reqorsa with AstraZeneca's Tagrisso and the latter with Genentech's Tecentriq, both showing good tolerability and early signs of efficacy.
- Long-term Treatment Effects: In the Acclaim-1 trial, one patient experienced over 42 months of progression-free survival following Reqorsa treatment, indicating that this therapeutic approach may offer significant long-term benefits for certain patients.
See More
Genprex Unveils Positive Data on Reqorsa Gene Therapy for Lung Cancer
- Preclinical Data Presentation: Genprex will present positive preclinical data on its lead drug candidate, Reqorsa, at the 2026 AACR Annual Meeting, indicating its multifaceted potential in treating non-small cell lung cancer, which could provide new therapeutic options for patients.
- Biomarker Discovery: Researchers identified TROP2 and PTEN as potential biomarkers for response to TUSC2 gene therapy, a finding that could refine patient selection strategies and enhance the therapeutic efficacy of Reqorsa, holding significant clinical application value.
- Enhanced Antitumor Activity: In mouse models, the combination of Quar Oze with other drugs resulted in a 79% tumor shrinkage, demonstrating its potential as an adjunct therapy, particularly for patients with resistance, which is crucial for advancing treatment options.
- Immune Enhancement Effects: The restoration of TUSC2 significantly boosted natural killer cell cytotoxicity, indicating that Reqorsa not only targets tumor cells directly but also activates the immune system, supporting its development as a dual-function therapeutic approach.
See More
Genprex to Participate in BIO Europe Spring Conference
- Executive Attendance: Genprex's CEO Ryan Confer and Senior VP of Intellectual Property Thomas Gallagher will attend the BIO Europe Spring conference in Lisbon from March 23-25, 2026, showcasing the company's advancements in gene therapies for cancer and diabetes to attract potential investors and partners.
- One-on-One Meeting Opportunities: Throughout the conference, Genprex executives will conduct one-on-one meetings with industry groups to provide an overview of the company's gene therapies, with over 3,700 executives from biotech, pharma, and finance expected to participate, fostering business development and collaboration opportunities.
- Clinical Trial Progress: Genprex's lead product candidate, Reqorsa® gene therapy, is currently undergoing two clinical trials for NSCLC and SCLC, both of which have received FDA Fast Track Designation, indicating the company's potential and competitiveness in the cancer treatment market.
- Diabetes Treatment Innovation: Genprex's diabetes gene therapy GPX-002 delivers Pdx1 and MafA genes directly to the pancreas through a novel infusion process, aiming to transform pancreatic alpha cells into functional beta-like cells, potentially offering new treatment options for diabetes patients and enhancing the company's position in the diabetes treatment market.
See More
